WINNIPEG, MB, Nov. 18, 2020 /CNW/ - Medicure Inc. ("Medicure"
or the "Company") (TSXV: MPH) (OTC: MCUJF), a cardiovascular
pharmaceutical company, today announces that its subsidiary,
Medicure International Inc., has settled its ongoing patent
infringement action against Nexus Pharmaceuticals, Inc. ("Nexus")
in the U.S. District Court for the Northern District of
Illinois, which alleged
infringement of Medicure's U.S. Patent No. 6,770,660 ("the
'660 patent"). As part of the settlement, Nexus has acknowledged
that the '660 patent is valid, enforceable and infringed. The
settlement results in the Company entering into a license agreement
with Nexus with anticipated launch dates for Nexus' generic
products of November 1, 2022 for the 5 mg strength and
January 1, 2023 for the 12.5 mg
strength. The remaining terms of the settlement are
confidential.
"We are pleased that we were able to settle this litigation in a
cost-effective manner while protecting our AGGRASTAT brand and its
intellectual property." stated Dr. Albert
Friesen, Chief Executive Officer of the Company and Chair of
its Board of Directors.
The Company had filed the patent infringement action against
Nexus alleging infringement of the '660 patent. The patent
infringement action was in response to Nexus' filing of an
abbreviated new drug application (ANDA) seeking approval from the
U.S. Food and Drug Administration ("FDA") to market a generic
version of AGGRASTAT® (tirofiban hydrochloride)
injection before the expiration of the '660 patent. The '660 patent
is listed in the FDA's orange book with an expiry date of
May 1, 2023.
AGGRASTAT® is a platelet aggregation inhibitor
indicated to reduce the rate of thrombotic cardiovascular events
(combined endpoint of death, myocardial infarction, or refractory
ischemia/repeat cardiac procedure) in patients with non-ST
elevation acute coronary syndrome (NSTE-ACS).
About Medicure Inc.
Medicure is a pharmaceutical
company focused on the development and commercialization of
therapies for the U.S. cardiovascular market. The present focus of
the Company is the marketing and distribution of
AGGRASTAT® (tirofiban hydrochloride) injection and
ZYPITAMAGTM (pitavastatin) tablets in the United States, where they are sold through
the Company's U.S. subsidiary, Medicure Pharma Inc. For more
information on Medicure please visit www.medicure.com.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
View original
content:http://www.prnewswire.com/news-releases/medicure-announces-settlement-of-patent-infringement-action-301176527.html
SOURCE Medicure Inc.